Psma1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [1]
PSMA1 (Proteasome Subunit Alpha Type 1) encodes the α1 subunit of the 20S proteasome core particle, a crucial component of the ubiquitin-proteasome system (UPS) responsible for targeted protein degradation in all eukaryotic cells. In the brain, PSMA1 is expressed in neurons and glia where it plays essential roles in maintaining protein homeostasis), clearing misfolded proteins, and regulating synaptic function. Dysfunction of PSMA1 and the proteasome complex is strongly implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease. [2]
| Property | Value | [3]
|----------|-------| [4]
| Protein Name | Proteasome Subunit Alpha Type 1 |
| Gene | PSMA1 |
| UniProt ID | P25786 |
| PDB ID | 5MX3 |
| Molecular Weight | 27.6 kDa |
| Subcellular Localization | Cytoplasm, Nucleus |
| Protein Family | Proteasome alpha subunit family |
| Expression | Ubiquitous, high in brain |
The PSMA1 protein is a 263-amino acid subunit that adopts the classic α/β fold shared by all proteasome subunits. Each subunit contains an N-terminal threonine residue (Thr1) that serves as the catalytic nucleophile for proteolysis.
The 20S proteasome forms a barrel-shaped complex composed of four stacked heptameric rings:
The α-rings regulate substrate access through the gated channel mechanism, controlled by regulatory particles (19S/PA700) or proteasome activators (PA28/11S, Blm10/PA200).
PSMA1 undergoes various modifications including:
PSMA1 is essential for proteasome assembly and catalytic function:
Proteasome dysfunction is a hallmark of AD brains:
The proteasome is a therapeutic target:
The study of Psma1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Nguyen P, Barakat A, Mook-Jung I. Proteasome modulation as a therapeutic approach in Alzheimer's disease. Front Aging Neurosci. 2021;13:630853. 2021. ↩︎
Kikuchi M, et al. Proteasome impairment in neural cells by amyloid-beta peptide. J Neurochem. 2020;152(3):381-395. 2020. ↩︎
Deng H, et al. TDP-43 pathology in ALS: proteasome impairment and stress granule formation. Acta Neuropathol. 2021;141(2):173-186. 2021. ↩︎
Sitte S, et al. Proteasome inhibition leads to early synaptic dysfunction in Huntington's disease. J Neurosci. 2020;40(12):2412-2424. 2020. ↩︎